Uterine fibroid-treating device developer Mirabilis Medica raised $5.2 million in a new round of debt financing, according to an SEC filing posted today.

The company’s Mirabilis system is designed to use ultrasound to both provide imaging and ablation during procedures to remove uterine fibroids, the company said.

The device uses low-intensity ultrasound waves to locate fibroids within the body, and a high-intensity ultrasound to heat and kill the fibroid tissue to provide relief from symptoms due to the growths, according to the company’s site.

Money in the round came from 3 unnamed investors, according to the SEC filings, with the company looking to raise another $14.8 million before the round closes.

Bothell, Wash.-based Mirabilis Medica has not yet announced how it plans to spend funds from the round.